UGISense AG develops new and innovative antisense drugs in collaboration with partners from industry and academia. The developments are made on the basis of a proprietary platform technology, i.e. the Ugimers. The company, first established in 2016, is being financed by private investors, the Lead Discovery Center GmbH and the SeedCapital Dortmund II GmbH & Co. KG.
|Company name||UGISense AG|
|Zip Code & City||44227 Dortmund|
|Name||Frau Dr. Birgit Werner|